Skip to main content
Home > BioCentury on BioBusiness > Cover Story

Chronological Index of : Cover Story

 Current Issue
  • Table: Platform efficiencies

    Haste, not waste Platform efficiencies Platform trials can identify an effective therapy with fewer patients in less time and with a higher probability of success than a traditional two-arm study testing one drug …

    Published on 9/5/2016
  • Table: Platform prototypes

    Haste, not waste Platform prototypes At least seven platform studies that simultaneously test multiple therapies from different companies are ongoing or planned. The trials achieve operational efficiencies by …

    Published on 9/5/2016
  • Northern Lights 2.0

    A deep dive into the to-do list for Scandinavia's new ecosystem creators

    Players in the new Scandinavian ecosystem are making sure biotechs can get seed money and advance assets that are globally attractive.

    Published on 8/22/2016
  • Figure: Scandinavian Venture Financings

    Northern Lights 2.0 Scandinavian Venture Financings After a series of lean years in the late 2000s, when many VCs that previously injected money into Scandinavia ceased operations, the region has seen a resurgence…

    Published on 8/22/2016
  • Serving returns

    How Ally Bridge expects to build on top of WuXi arbitrage play

    As Ally Bridge waits for WuXi to bear fruit, its next returns could come from transformative data events elsewhere in its portfolio.

    Published on 8/15/2016
  • Table: Ally Bridge's portfolio

    Serving returns Ally Bridge's portfolio Ally Bridge Group has disclosed investments in at least 17 biotech companies, several of which are developing potentially first-in-class or best-in-class technologies. …

    Published on 8/15/2016
  • Better Modeling Through PDUFA

    How PDUFA VI could improve drug development via better models, innovative trials

    PDUFA VI aims to boost the use of modeling and simulations, along with novel clinical trial designs, to improve the speed and outcomes of clinical development.

    Published on 8/8/2016
  • Box: Panic and forget it

    Bug battle plan Panic and forget it The history of emerging infectious disease outbreaks over the past few decades reveals a consistent pattern. They start with a disease that has been previously identified but …

    Published on 8/1/2016
  • Box: Trying SAM

    Bug battle plan Trying SAM GlaxoSmithKline plc isn't waiting until it lines up funding for its proposed BioPreparedness Organization to start R&D on new vaccines for emerging infectious diseases. In July, GSK …

    Published on 8/1/2016
  • Bug battle plan

    GSK hoping a government funded unit will battle infectious diseases threats

    GSK is seeking government funding to create a BioPreparedness Organization to develop vaccines for emerging infectious diseases.

    Published on 8/1/2016
  • Paving the way

    How Amgen, Sandoz IP battles may unleash a flood of Humira, Enbrel biosimilars

    Amgen and Sandoz are likely to gain approval of biosimilar versions of Humira and Enbrel, but they won't have the U.S. market to themselves for long.

    Published on 7/25/2016
  • Table: Enbrel biosimilars

    Paving the way Enbrel biosimilars At least nine programs have made it to the clinic with biosimilars of autoimmune drug Enbrel etanercept from Amgen Inc. (NASDAQ:AMGN). While the GP2015 BLA from the Sandoz unit of…

    Published on 7/25/2016
  • Table: Humira biosimilars

    Paving the way Humira biosimilars At least 16 biosimilars of Humira adalimumab from AbbVie Inc. (NYSE:ABBV) have made it into the clinic, including two that are approved in India. A BLA for ABP 501 from Amgen Inc.…

    Published on 7/25/2016
  • Eurosimilars

    Why it's hard to extrapolate European biosimilars market penetration to the U.S.

    European biosimilars market penetration and prices are all over the map, making it hard to extrapolate the EU experience to the U.S.

    Published on 7/25/2016
  • PRO-fessional label

    How a new PRO could end up on cancer drug labels

    FDA is hopeful that data from a new PRO launched by NCI could find its way onto drug labels in the next year or two.

    Published on 7/18/2016
  • Shedding red

    Biotech winners, losers in 2Q16

    Brexit soured what looked to be a rebound quarter for biotech.

    Published on 7/11/2016
  • Figure: Biotech fund flows

    Ground up Biotech fund flows Biotech funds have seen net outflows in every month of 2016, though the outflow of $933.3 million in 2Q16 was less than either of the first two months of the year. In 1H15, fund …

    Published on 7/11/2016
  • Table: Follow-on performance

    Ground up Follow-on performance Thirty-seven biotechs raised a combined $2.1 billion in follow-ons last quarter, bringing the total for 1H16 to $3.9 billion. In 1H15, 150 companies raised $19 billion. The 2Q16 …

    Published on 7/11/2016
  • Table: IPO performance

    Ground up IPO performance Sixteen biotechs raised $767.5 million in IPOs last quarter, bringing the total raised in 1H16 to $1.4 billion. In 1H15, there were 50 biotech IPOs that raised a total of $5 billion. The …

    Published on 7/11/2016
  • Table: IPO queue

    Ground up IPO queue At least eight companies have announced plans to go public since the start of 2Q16, bringing the IPO queue to at least 23. Unless noted, companies are seeking to list on NASDAQ. Filings are …

    Published on 7/11/2016
  • Ground up

    How biotech stocks may navigate post-Brexit, pre-election waters

    Biotech stocks are shaking off a Brexit hangover while facing a presidential election overhang. Both have curbed generalists' appetite for risk.

    Published on 7/11/2016
  • Rethinking risk

    Investors' top names and milestones in 3Q16

    Going into 2H16, some buysiders want companies that have turned over their data cards. Others are combing a plethora of Phase II and III events for upside.

    Published on 7/11/2016
  • Figure: London vs. Europe

    Shedding red London vs. Europe The BioCentury Europe index rose 9% in 2Q16, as 10 of 19 continental European companies in the market cap-weighted index showed gains. The big driver was Genmab A/S (CSE:GEN), which …

    Published on 7/11/2016
  • Figure: Price-to-earnings: BT vs. RX

    Shedding red Price-to-earnings: BT vs. RX Biotech's average P/E ended 2Q at 24, up 16% from 1Q16 and down 8% from a year ago. The 2Q16 average is inflated by Vertex Pharmaceuticals Inc. (NASDAQ:VRTX). Backing out …

    Published on 7/11/2016
  • Figure: Results by market cap

    Shedding red Results by market cap Companies in the $1-$4.9 billion market cap segment were the best performing band in 2Q, finishing the quarter up a median of 1.9%. The $500-$999 million segment and those valued…

    Published on 7/11/2016

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993